Patents Assigned to Achillion Pharmaceuticals, Inc.
-
Publication number: 20150239895Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Jason Allan Wiles, Avinash S. Phadke
-
Publication number: 20150239868Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an alkyne (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Godwin Pais, Akihiro Hashimoto, Venkat Rao Gadhachanda, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke, Jason Allan Wiles
-
Publication number: 20150239837Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Jason Allan Wiles, Milind Deshpande
-
Publication number: 20150239920Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: Achillion Pharmaceuticals, Inc.Inventors: Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke, Jason Allan Wiles
-
Publication number: 20150239919Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is a carbamate, ester, or ketone substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke, Jason Allan Wiles
-
Publication number: 20150239893Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Qiuping Wang, Venkat Rao Gadhachanda, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke, Jason Allan Wiles
-
Publication number: 20150239921Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Jason Allan Wiles, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
-
Publication number: 20150239894Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.Type: ApplicationFiled: February 25, 2015Publication date: August 27, 2015Applicant: ACHILLION PHARMACEUTICALS, INC.Inventors: Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Jason Allan Wiles, Avinash S. Phadke
-
Patent number: 9115175Abstract: The disclosure includes novel processes for producing Sovaprevir comprising adding compound E to F-1 to provide Sovaprevir. The disclosure further includes intermediates useful for producing Sovaprevir. The disclosure also include a novel crystalline form of Sovaprevir, Form F, and a method for preparing spray-dried amorphous Sovaprevir from crystalline Form F.Type: GrantFiled: March 14, 2014Date of Patent: August 25, 2015Assignee: ACHILLION PHARMACEUTICALS, INC.Inventors: Avinash Phadke, Akihiro Hashimoto, Venkat Gadhachanda
-
ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
Patent number: 9085607Abstract: The disclosure provides a crystalline sodium salt of ACH-0142684 comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with FIGS. 8; 12; 15; 21; 22; 27; 30, and 31, respectively.Type: GrantFiled: March 17, 2014Date of Patent: July 21, 2015Assignee: ACHILLION PHARMACEUTICALS, INC.Inventors: Avinash Phadke, Akihiro Hashimoto, Pingyun Chen, Senthil Kumar Kusalakumari Sukumar -
Patent number: 9006423Abstract: The invention provides a process of preparing 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Compound I and pharmaceutically acceptable salts thereof.Type: GrantFiled: March 17, 2014Date of Patent: April 14, 2015Assignee: Achillion Pharmaceuticals Inc.Inventors: Avinash Phadke, Akihiro Hashimoto
-
Patent number: 8946422Abstract: The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R2, R3, R5, R6, R7, and R9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.Type: GrantFiled: October 24, 2011Date of Patent: February 3, 2015Assignee: Achillion Pharmaceuticals, Inc.Inventors: Barton James Bradbury, Jason Allan Wiles, Qiuping Wang, Akhiro Hashimoto, Edlaine Lucien, Godwin Clarence Gilroy Pais, Milind Deshpande, Micheal John Pucci, Ha Young Kim
-
Publication number: 20140309164Abstract: Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure The variables, e.g., B1, Y, R1, R2, R3, R3?, R4, R5, R6, R7, R8, and R9 carry definitions set forth in the disclosure. Compounds of Formula (I) are deuterated at one or more positions and the deuterium enrichment at each deuterated positions is at least 50%. Compounds and salts of Formula (I) are useful for treating viral infections, including HCV infections.Type: ApplicationFiled: April 14, 2014Publication date: October 16, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventors: Milind Deshpande, Jason Allan Wiles, Akihiro Hashimoto, Avinash Phadke
-
Publication number: 20140309189Abstract: A deuterated nucleoside analog of the formula and the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a carrier. Compounds and salts of this formula are useful for treating viral infections, including HCV infections. A method for treating a host afflicted with hepatitis C or other disorders is also presented that includes administering an effective treatment amount of a nucleoside or nucleotide that has deuterium with at least 50% enrichment at the 5?-position of the nucleoside or nucleotide.Type: ApplicationFiled: April 14, 2014Publication date: October 16, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventors: Milind Deshpande, Jason Allan Wiles, Akihiro Hashimoto, Avinash Phadke
-
Publication number: 20140275520Abstract: The invention provides a process of preparing 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Compound I and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventors: Avinash Phadke, Akihiro Hashimoto
-
Publication number: 20140275163Abstract: The disclosure provides crystalline Sovaprevir forms. The crystalline forms of Sovaprevir comprise a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, and a Form E polymorph. The Form A, B, C, D, and E polymorphs exhibit X-ray powder diffraction patterns having peak locations in accordance with FIGS. 1, 4, 7, 10, and 13, respectively.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventor: Avinash Phadke
-
ACH-0142684 SODIUM SALT POLYMORPH, COMPOSITION INCLUDING THE SAME, AND METHOD OF MANUFACTURE THEREOF
Publication number: 20140274914Abstract: The disclosure provides a crystalline sodium salt of ACH-0142684 comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with FIGS. 8; 12; 15; 21; 22; 27; 30, and 31, respectively.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: Achillion Pharmaceuticals Inc.Inventors: Avinash Phadke, Akihiro Hashimoto, Pingyun Chen, Senthil Kumar Kusalakumari Sukumar -
Publication number: 20140275480Abstract: The disclosure includes novel processes for producing Sovaprevir comprising adding compound E to F-1 to provide Sovaprevir. The disclosure further includes intermediates useful for producing Sovaprevir. The disclosure also include a novel crystalline form of Sovaprevir, Form F, and a method for preparing spray-dried amorphous Sovaprevir from crystalline Form F.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventors: Avinash Phadke, Akihiro Hashimoto, Venkat Gadhachanda
-
Publication number: 20140271855Abstract: The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Achillion Pharmaceuticals Inc.Inventors: Jennifer Hsing-Chung Chu, Gautam Shah, Avinash Phadke
-
Patent number: 8835456Abstract: The invention provides compounds of Formula I and the pharmaceutically salts thereof. These compounds may be generally described as bridged-bicyclo indole-containing compounds. The variables shown in Formula I are defined herein. Certain compounds of Formula I are useful as antiviral agents. Compounds as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I and at least one pharmaceutically acceptable carrier. Such pharmaceutical compositions may contain a compound of Formula I as the only active agent or may contain a combination of a compound of Formula I and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.Type: GrantFiled: March 19, 2012Date of Patent: September 16, 2014Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Venkat Gadhachanada, Avinash Phadke, Milind Deshpande, Dawei Chen